NEU.AX - Neuren Pharmaceuticals Limited

ASX - ASX Delayed price. Currency in AUD

Neuren Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
61 3 9092 0480

Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Richard Spencer Treagus B.Sc., M.B.A., BScMed, MBChB, MPharmMed, MBAExec. ChairmanN/AN/AN/A
Mr. Lawrence GlassChief Science OfficerN/AN/AN/A
Mr. Jonathan Charles Pilcher BSc (Hons), ACACFO & Company Sec.N/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

Corporate governance

Neuren Pharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.